Loading...
Children account for 19% of all COVID-19 cases in the U.S., with just over 1000 pediatric deaths since the pandemic began (https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/). The BNT162b2 (Pfizer-BioNTech) vaccine has been available under emergency use authorization for children aged >12 years since May 2021 and for children aged 5–11 years since October 2021.
The coronavirus efficacy (KidCOVE) trial of the mRNA-1273 (Moderna) vaccine was conducted during the period of Delta predominance and included open-label (50 μg vs. 100 μg) and placebo-controlled phases to test safety and immune response of the 50 μg dose in almost 4800 children aged 6–23 months, 2–5 years, and 6–11 y…